Globus Medical Inc. Class A Common Stock vs MP Materials — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while MP Materials trades at $39.3 (market cap $7.56B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and MP Materials for 14 Days on average.
| GMED | MP | |
|---|---|---|
Market Cap | $10.25B | $7.56B |
Volume | 1,108,124 | 5,062,845 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $89.85 |
52-Week Low | $58.33 | $38.10 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $9.76B | $7.04B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MP Materials (MP) trades at $42.43, down 2.14% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability metrics with a -19.85% net income margin and -4.08% ROE, though revenue growth is projected from $224M in 2025 to $305M in 2026. Analyst sentiment remains strongly bullish with 13 buy ratings and a $80.70 consensus price target, representing significant upside potential from current levels despite recent price weakness.
The investment case hinges on MP's strategic position in rare earths production and U.S. government support for domestic supply chains. Key risks include persistent negative cash flow from operations, high valuation multiples (P/S 24.64), and sector volatility. The upcoming Q3 2026 earnings report on November 5 will be critical for validating the company's growth trajectory and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →